W. Hiddemann

发表

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros

C. Pott, M. Dreyling, F. Hartmann, 2006, Blood.

Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma.

W. Hiddemann, C. Buske, M. Dreyling, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.

W. Hiddemann, K. Spiekermann, F. Alves, 1999, Experimental hematology.

Newly diagnosed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

W. Hiddemann, M. Dreyling, M. Dreyling, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

W. Hiddemann, C. Pott, S. Hermann, 2002, Deutsche medizinische Wochenschrift.

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros

W. Hiddemann, M. Qumsiyeh, H. Einsele, 2006, Blood.

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.

M. Tiemann, W. Hiddemann, R. Herrmann, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mantle cell lymphoma: established therapeutic options and future directions

W. Hiddemann, G. Lenz, M. Dreyling, 2004, Annals of Hematology.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

N. Schmitz, W. Hiddemann, M. Boccadoro, 2005, Blood.

Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.

W. Hiddemann, B. Dörken, C. Köhne, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).

E. Hoster, J. Braess, M. Sauerland, 2006, Blood.

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies

W. Hiddemann, V. Heinemann, T. Kirchner, 2009 .

Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

W. Hiddemann, K. Spiekermann, C. Haferlach, 2012, Bone Marrow Transplantation.